AKT1 and neoplasm: As it has been hypothesized that the tumor suppressor PTEN is the main node in the PI3K–AKT inhibitory network (21), patients with PTEN loss may demonstrate high PI3K pathway activation, which may be inhibited effectively by copanlisib.